Physiomics (LSE:PYC) Tariff Resilience Score: 0/10 (As of Jul. 07, 2026)


What is Physiomics Tariff Resilience Score?

Physiomics has the Tariff Resilience Score of 0, which implies that the company might have .

Physiomics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Physiomics might have .

Physiomics  (LSE:PYC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Physiomics Tariff Resilience Score Related Terms

Physiomics Business Description

Other Exchanges RVW1:Germany
Address 140 Eastern Avenue, Bee House, Milton Park, Abingdon, GBR, OX14 4SB
Physiomics PLC is a United Kingdom-based firm that provides consulting services to biopharmaceutical companies and research institutes in the areas of outsourced modelling and simulation (quantitative pharmacology), biometrics, and data science (bioinformatics). Its business activities involve the use of industry-standard technologies and a proprietary technology platform called Virtual Tumour. The company has three service lines: Biometrics, Modelling and Simulation (Quantitative Pharmacology) and Personalised Medicine. It derives revenue from the UK, the European Union and Switzerland.